CD8A and cancer: PD-1, a pivotal co-inhibitory receptor on activated T cells, interacts with overexpressed programmed cell death ligand 1 (PD-L1) on cancer cells, tumor-infiltrating lymphocytes, and stromal cells, detrimentally affecting the cytotoxicity of CD8+ T cells and consequently mediating immunosuppressive responses [20].